company background image
3320 logo

China Resources Pharmaceutical Group SZSC:3320 Stock Report

Last Price

HK$5.43

Market Cap

HK$34.1b

7D

0.4%

1Y

12.4%

Updated

22 Dec, 2024

Data

Company Financials +

China Resources Pharmaceutical Group Limited

SZSC:3320 Stock Report

Market Cap: HK$34.1b

3320 Stock Overview

An investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. More details

3320 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance5/6
Financial Health5/6
Dividends3/6

My Notes

Capture your thoughts, links and company narrative

China Resources Pharmaceutical Group Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for China Resources Pharmaceutical Group
Historical stock prices
Current Share PriceHK$5.43
52 Week HighHK$7.11
52 Week LowHK$4.45
Beta0.42
1 Month Change4.83%
3 Month Change10.82%
1 Year Change12.42%
3 Year Change64.05%
5 Year Change-23.41%
Change since IPO-39.73%

Recent News & Updates

Recent updates

Shareholder Returns

3320HK PharmaceuticalsHK Market
7D0.4%-1.9%-0.5%
1Y12.4%-3.9%19.9%

Return vs Industry: 3320 exceeded the Hong Kong Pharmaceuticals industry which returned -3.9% over the past year.

Return vs Market: 3320 underperformed the Hong Kong Market which returned 19.9% over the past year.

Price Volatility

Is 3320's price volatile compared to industry and market?
3320 volatility
3320 Average Weekly Movement6.4%
Pharmaceuticals Industry Average Movement6.4%
Market Average Movement8.8%
10% most volatile stocks in HK Market18.6%
10% least volatile stocks in HK Market4.1%

Stable Share Price: 3320 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 3320's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200772,764Xiaosong Baiwww.crpharm.com

China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and v, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular, alimentary tract, metabolism and endocrine, respiratory, orthopedics, oncology, medical nutrition, gastroenterology, pediatrics, genitourinary system, cough and cold, anti-infection, dermatology, infusion solutions, etc. It provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies.

China Resources Pharmaceutical Group Limited Fundamentals Summary

How do China Resources Pharmaceutical Group's earnings and revenue compare to its market cap?
3320 fundamental statistics
Market capHK$34.11b
Earnings (TTM)HK$4.03b
Revenue (TTM)HK$266.95b

8.5x

P/E Ratio

0.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
3320 income statement (TTM)
RevenueCN¥250.48b
Cost of RevenueCN¥210.97b
Gross ProfitCN¥39.51b
Other ExpensesCN¥35.73b
EarningsCN¥3.78b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.60
Gross Margin15.77%
Net Profit Margin1.51%
Debt/Equity Ratio77.1%

How did 3320 perform over the long term?

See historical performance and comparison

Dividends

3.3%

Current Dividend Yield

39%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 12:36
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

China Resources Pharmaceutical Group Limited is covered by 20 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bo LiBofA Global Research
Shun Kei LawCCB International Securities Limited
Zhishun SiuCCB International Securities Limited